Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v26.i4.10
pages 333-372

Paclitaxel in Cancer Treatment: Perspectives and Prospects of its Delivery Challenges

Somnath Singh
Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, Omaha, Nebraska
Alekha K. Dash
Creighton University

ABSTRACT

Paclitaxel (PTX) is a potent anticancer agent whose clinical usefulness is marred by a delivery problem that is caused by its unfavorable pharmacokinetic and physical properties. Paclitaxel is currently formulated in a mixture of Cremophor EL and ethanol, which is diluted 5−20 times with normal saline or 5% dextrose prior to administration via slow infusion to avoid precipitation in plasma. Many adverse reactions to the PTX formulation have been reported because of the presence of Cremophor EL, including hypersensitivity reactions, nephrotoxicity, and neurotoxicity. Cremophor EL also causes vasodilation, labored breathing, lethargy, hypotension, and leaching of plasticizers, such as diethylhexylpthalate, from the polyvinylchloride infusion bags/sets. Significant research efforts have been conducted to develop an alternative formulation approach to increase the aqueous solubility of PTX without using Cremophor, thereby decreasing its toxicity. This article reviews the various investigated formulation approaches including pastes; liposomes; conjugates with antibodies, peptides, and fatty acids; nanospheres and microspheres; cyclodextrin complexes; emulsions; mucoadhesive gel; prodrugs; and nanoparticulate systems. The pros and cons of each approach are also discussed. Finally, this review concludes with a discussion of nanoparticulate delivery, which is the most promising PTX delivery system of the future because it incorporates the benefits of other approaches such as conjugation, complexation, and prodrugs.


Articles with similar content:

Solid Self-Nanoemulsifying Delivery Systems as a Platform Technology for Formulation of Poorly Soluble Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 1
Farhan Jalees Ahmad, Gulam Mustafa, Tripta Bansal, Sushama Talegaonkar, Zeenat I. Khan, Roop K. Khar
Improved Drug Delivery Using Microemulsions: Rationale, Recent Progress, and New Horizons
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.18, 2001, issue 1
J. R. Kanicky, D. O. Shah, P. K. Patanjali, B. J. Palla, R. P. Bagwe
Drug Delivery to the Nail: Therapeutic Options and Challenges for Onychomycosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 6
Bhavesh S. Barot, Pragna K. Shelat, Hetal K. Patel, Dharmik M. Mehta, Punit B. Parejiya
Mucosal Drug Delivery: Membranes, Methodologies, and Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.21, 2004, issue 3
Bozena Michniak, Yifan Song, Rashmi Thakur, Victor M. Meidan, Yiping Wang
Emerging Potential of Nanosuspension-Enabled Drug Delivery: An Overview
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 6
Vivek Ranjan Sinha, Silki